Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (FDA) for Triamcinolone Acetonide ointment USP, 0.5%, the generic version of Triamcinolone Acetonide ointment USP, 0.5% of Perrigo New York, Inc.

According to IMS Health sales data for the 12 month period ending May 2016, the Triamcinolone Acetonide ointment USP, 0.5% market achieved annual sales of approximately $4.4 million.

Glenmark’s current portfolio consists of 116 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.